JPMA: It Is Up To Companies How They Follow Transparency Guidelines
This article was originally published in PharmAsia News
JPMA Managing Director Tokuo Tanaka told reporters Nov. 21 it is up to companies themselves to decide how they follow the association’s guidelines regarding the publication of information concerning funding given to doctors.
You may also be interested in...
National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.
Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.